Endoscopy 2019; 51(04): S140
DOI: 10.1055/s-0039-1681582
ESGE Days 2019 ePoster podium presentations
Friday, April 5, 2019 13:00 – 13:30: EUS FNA 1 ePoster Podium 5
Georg Thieme Verlag KG Stuttgart · New York

HIGH PERFORMANCE OF A NEW FRANSEEN NEEDLE FOR ENDOSCOPIC ULTRASOUND-GUIDED FINE-NEEDLE BIOPSY IN SOLID LESIONS: A RETROSPECTIVE MULTICENTER STUDY

G de Nucci
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese-Milano, Italy
,
G Del Vecchio Blanco
2   Tor Vergata University, Gastroenterology Unit, Rome, Italy
,
A Amato
3   Valduce Hospital, Gastroenterology Unit, Como, Italy
,
E Forti
4   Ca Grande Niguarda Hospital, Endoscopy Unit, Milan, Italy
,
G Santo Mezzi
5   Vimercate and Desio Civil Hospital, Gastroenterology and Endoscopy Unit, Vimercate, Italy
,
G Mogavero
3   Valduce Hospital, Gastroenterology Unit, Como, Italy
,
E Domenico Mandelli
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese-Milano, Italy
,
G Manes
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese-Milano, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. März 2019 (online)

Auch verfügbar auf
 

Aims:

Endoscopic ultrasound-guided fine needle aspiration (FNA) is the standard choice to sample gastrointestinal/pancreatic lesions. EUS-FNA is accurate when rapid on-site evaluation (ROSE) is performed, but ROSE is not always available. EUS-guided fine needle biopsy (EUS-FNB) can give a a better chance to reach a diagnosis providing more tissue. It is not simple to use 19-gauge needles especially in transduodenal settings for risk of complications.A new needle for EUS-FNB, the AcquireTM needle is available from 2016. Data for pancreatic and non pancreatic solid lesions are available but these are based only on small sample size studies. The aim of our study is to perform a retrospective evaluation of all sampling procedures performed using the 22/25 gauge AcquireTM needle in patients with solid lesions.

Methods:

We performed a retrospective analysis of prospective, multicentric databases in five Italian Endoscopic centres, including all consecutive patients with solid lesions who underwent EUS with tissue sampling 22/25-gauge Acquire needles between June 2016 and October 2018. All lesions localized at pancreas, nodes, biliary, kidney/liver masses, periduodenal/perigastric abdominal masses were enrolled in the study. Features of masses at EUS evaluations and technical details of FNB were recorded.

Results:

370 patients (60.2% males, mean age 64,3) were enrolled. EUS-FNB was performed using the 22 and 25 gauge AcquireTM needle. The biopsies was done transgastrically in 160 (43%) cases and transduodenally in 210 (57%) ones. A mean of 2.2 ± 0.32 passes per lesion site were performed, without any complication. A tissue core biopsy sample for histological evaluation was obtained in 362 (97%) cases. In all the cases, the specimens were useful for cytological analysis. Acquire sensitivity, specificity and diagnostic accuracy were 98.8%,100% and 98.7% respectively.

Conclusions:

EUS-FNB using the 22 and the 25-gauge AcquireTM needle has a very high accurancy and is useful to achieve histological sample in almost all the patients.